4D Molecular Therapeutics Inc. Common Stock (FDMT)

FairStock Score: 63/100 — STEADY

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.05, providing financial flexibility
• Superior net profit margin of 22.0% indicating pricing power and operational efficiency
• Revenue growth of 8508900.0% demonstrates strong top-line momentum

Concerns

• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

4D Molecular Therapeutics Inc. Common Stock is a micro-cap healthcare company valued at $497 million. The business generates $88 million in annual revenue with a 22.0% net margin. From a quality standpoint, 4D shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and healthy Altman Z-Score of 3.9. On valuation, the stock is solid 5.8% FCF yield. Growth dynamics show revenue growing at 8508900.0% and profit growth of 139.1%. Our composite FairStock Score of 63/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

4D's 8508900% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer